Base de dados : MEDLINE
Pesquisa : G12 [Categoria DeCS]
Referências encontradas : 236 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 24 ir para página                         

  1 / 236 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463238
[Au] Autor:Jonker I; Rosmalen JGM; Schoevers RA
[Ad] Endereço:Department of Psychiatry, Interdisciplinary Center for Psychopathology and Emotion Regulation (ICPE), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
[Ti] Título:Childhood life events, immune activation and the development of mood and anxiety disorders: the TRAILS study.
[So] Source:Transl Psychiatry;7(5):e1112, 2017 May 02.
[Is] ISSN:2158-3188
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The experience of childhood life events is associated with higher vulnerability to develop psychiatric disorders. One of the pathways suggested to lead to this vulnerability is activation of the immune system. The aim of this study is to find out whether the association between childhood life events and the development of mood and anxiety disorders is predicted by the activation of the immune system. This study was performed in TRAILS, a large prospective population cohort, from which a subgroup was selected (N=1084, 54.3% female, mean age 19.0 (s.d., 0.6)). Childhood life events before age 16 were assessed using questionnaires at age 12, 14, 16 and 19. Immune activation was assessed at age 16 by elevated high-sensitive C-reactive protein (hsCRP) and by levels of immunoglobulin G antibodies against the herpes viruses herpes simplex virus 1, cytomegalovirus and Epstein-Barr virus. At age 19, the presence of mood and anxiety disorders was determined using the World Health Organization Composite International Diagnostic Interview Version 3.0. Regression analyses were used to study the association between life events, the inflammatory markers and mental health. We found that childhood life events score was associated with risk of mood disorders (B=0.269, P<0.001) and anxiety disorders (B=0.129, P<0.001). Childhood life events score was marginally associated with elevated hsCRP (B=0.076, P=0.006), but not with the antibody levels. This was especially due to separation trauma (P=0.015) and sexual abuse (P=0.019). Associations lost significance after correcting for lifestyle factors such as body mass index and substance abuse (P=0.042). None of the inflammatory markers were associated with development of anxiety disorders or mood disorders. In conclusion, the life event scores predicted the development of anxiety disorders and mood disorders at age 19. Life event scores were associated with elevated hsCRP, which was partly explained by lifestyle factors. Elevated hsCRP was not associated with the development of psychiatric disorders at age 19.
[Mh] Termos MeSH primário: Afeto/fisiologia
Transtornos de Ansiedade/diagnóstico
Fenômenos do Sistema Imunológico/fisiologia
Acontecimentos que Mudam a Vida
Transtornos do Humor/diagnóstico
[Mh] Termos MeSH secundário: Adolescente
Transtornos de Ansiedade/epidemiologia
Transtornos de Ansiedade/imunologia
Transtornos de Ansiedade/metabolismo
Índice de Massa Corporal
Proteína C-Reativa/metabolismo
Feminino
Seres Humanos
Imunoglobulina G/metabolismo
Masculino
Transtornos do Humor/epidemiologia
Países Baixos
Valor Preditivo dos Testes
Estudos Prospectivos
Transtornos Relacionados ao Uso de Substâncias/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunoglobulin G); 9007-41-4 (C-Reactive Protein)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1038/tp.2017.62


  2 / 236 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28934357
[Au] Autor:Ragland SA; Criss AK
[Ad] Endereço:Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia, United States of America.
[Ti] Título:From bacterial killing to immune modulation: Recent insights into the functions of lysozyme.
[So] Source:PLoS Pathog;13(9):e1006512, 2017 Sep.
[Is] ISSN:1553-7374
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Lysozyme is a cornerstone of innate immunity. The canonical mechanism for bacterial killing by lysozyme occurs through the hydrolysis of cell wall peptidoglycan (PG). Conventional type (c-type) lysozymes are also highly cationic and can kill certain bacteria independently of PG hydrolytic activity. Reflecting the ongoing arms race between host and invading microorganisms, both gram-positive and gram-negative bacteria have evolved mechanisms to thwart killing by lysozyme. In addition to its direct antimicrobial role, more recent evidence has shown that lysozyme modulates the host immune response to infection. The degradation and lysis of bacteria by lysozyme enhance the release of bacterial products, including PG, that activate pattern recognition receptors in host cells. Yet paradoxically, lysozyme is important for the resolution of inflammation at mucosal sites. This review will highlight recent advances in our understanding of the diverse mechanisms that bacteria use to protect themselves against lysozyme, the intriguing immunomodulatory function of lysozyme, and the relationship between these features in the context of infection.
[Mh] Termos MeSH primário: Anti-Infecciosos/farmacologia
Bactérias/efeitos dos fármacos
Infecções Bacterianas/imunologia
Fenômenos do Sistema Imunológico/efeitos dos fármacos
Muramidase/metabolismo
Peptidoglicano/metabolismo
[Mh] Termos MeSH secundário: Animais
Bactérias/imunologia
Infecções Bacterianas/tratamento farmacológico
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Peptidoglycan); EC 3.2.1.17 (Muramidase)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170922
[St] Status:MEDLINE
[do] DOI:10.1371/journal.ppat.1006512


  3 / 236 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28300664
[Au] Autor:Hall SM; Coulter SJ; Knudsen GA; Sanders JM; Birnbaum LS
[Ad] Endereço:Laboratory of Toxicology and Toxicokinetics, National Cancer Institute at the National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, NC 27709, United States.
[Ti] Título:Gene expression changes in immune response pathways following oral administration of tetrabromobisphenol A (TBBPA) in female Wistar Han rats.
[So] Source:Toxicol Lett;272:68-74, 2017 Apr 15.
[Is] ISSN:1879-3169
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Tetrabromobisphenol A (TBBPA) is a brominated flame retardant used globally at high volumes, primarily in the epoxy resin of circuit boards. It has been detected in the environment and in humans. The National Toxicology Program found that chronic oral TBBPA treatment of 250mg/kg and higher caused an increased incidence of uterine lesions in female Wistar Han rats. The present laboratory has previously reported changes in gene expression associated with estrogen homeostasis in liver and uterine tissue of adult female Wistar Han rats after five days of gavage with 250mg/kg of TBBPA. Microarray analysis of tissue from these same TBBPA-treated rats was performed to detect additional pathways perturbed by TBBPA. Microarray analysis of uterine tissue detected downregulation of genes in pathways of the immune response following TBBPA treatment. These results, along with validation of associated gene expression changes using droplet digital PCR, are reported here. Our findings suggest mechanisms that may be related to estrogen-mediated immunosuppression.
[Mh] Termos MeSH primário: Retardadores de Chama/toxicidade
Fenômenos do Sistema Imunológico/efeitos dos fármacos
Fígado/efeitos dos fármacos
Bifenil Polibromatos/toxicidade
Transcriptoma/efeitos dos fármacos
Útero/efeitos dos fármacos
[Mh] Termos MeSH secundário: Administração Oral
Animais
Feminino
Fenômenos do Sistema Imunológico/genética
Fígado/imunologia
Ratos Wistar
Útero/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Flame Retardants); 0 (Polybrominated Biphenyls); FQI02RFC3A (tetrabromobisphenol A)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170626
[Lr] Data última revisão:
170626
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170317
[St] Status:MEDLINE


  4 / 236 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28295777
[Au] Autor:Olsson AG; Angelin B; Assmann G; Binder CJ; Björkhem I; Cedazo-Minguez A; Cohen J; von Eckardstein A; Farinaro E; Müller-Wieland D; Parhofer KG; Parini P; Rosenson RS; Starup-Linde J; Tikkanen MJ; Yvan-Charvet L
[Ad] Endereço:Department of Medicine and Health, Linköping University, Linköping, Sweden.
[Ti] Título:Can LDL cholesterol be too low? Possible risks of extremely low levels.
[So] Source:J Intern Med;281(6):534-553, 2017 Jun.
[Is] ISSN:1365-2796
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Following the continuous accumulation of evidence supporting the beneficial role of reducing low-density lipoprotein cholesterol (LDL-C) levels in the treatment and prevention of atherosclerotic cardiovascular disease and its complications, therapeutic possibilities now exist to lower LDL-C to very low levels, similar to or even lower than those seen in newborns and nonhuman species. In addition to the important task of evaluating potential side effects of such treatments, the question arises whether extremely low LDL-C levels per se may provoke adverse effects in humans. In this review, we summarize information from studies of human cellular and organ physiology, phenotypic characterization of rare genetic diseases of lipid metabolism, and experience from clinical trials. Specifically, we emphasize the importance of the robustness of the regulatory systems that maintain balanced fluxes and levels of cholesterol at both cellular and organismal levels. Even at extremely low LDL-C levels, critical capacities of steroid hormone and bile acid production are preserved, and the presence of a cholesterol blood-brain barrier protects cells in the central nervous system. Apparent relationships sometimes reported between less pronounced low LDL-C levels and disease states such as cancer, depression, infectious disease and others can generally be explained as secondary phenomena. Drug-related side effects including an increased propensity for development of type 2 diabetes occur during statin treatment, whilst further evaluation of more potent LDL-lowering treatments such as PCSK9 inhibitors is needed. Experience from the recently reported and ongoing large event-driven trials are of great interest, and further evaluation including careful analysis of cognitive functions will be important.
[Mh] Termos MeSH primário: LDL-Colesterol/sangue
[Mh] Termos MeSH secundário: Osso e Ossos/metabolismo
Encéfalo/fisiologia
Doenças Cardiovasculares/prevenção & controle
Diabetes Mellitus Tipo 2/sangue
Seres Humanos
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Hipercolesterolemia/sangue
Hipercolesterolemia/tratamento farmacológico
Fenômenos do Sistema Imunológico
Lipoproteínas LDL/sangue
Mutação
Neoplasias/sangue
Pró-Proteína Convertase 9/genética
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cholesterol, LDL); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Lipoproteins, LDL); EC 3.4.21.- (PCSK9 protein, human); EC 3.4.21.- (Proprotein Convertase 9)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170705
[Lr] Data última revisão:
170705
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE
[do] DOI:10.1111/joim.12614


  5 / 236 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28246613
[Au] Autor:Balzar S
[Ad] Endereço:Department of Clinical Microbiology, Polyclinic Breyer, Zagreb, Croatia.
[Ti] Título:Continuous Dual Resetting of the Immune Repertoire as a Basic Principle of the Immune System Function.
[So] Source:J Immunol Res;2017:3760238, 2017.
[Is] ISSN:2314-7156
[Cp] País de publicação:Egypt
[La] Idioma:eng
[Ab] Resumo:Idiopathic chronic inflammatory conditions (ICIC) such as allergy, asthma, chronic obstructive pulmonary disease, and various autoimmune conditions are a worldwide health problem. Understanding the pathogenesis of ICIC is essential for their successful therapy and prevention. However, efforts are hindered by the lack of comprehensive understanding of the human immune system function. In line with those efforts, described here is a concept of stochastic continuous dual resetting (CDR) of the immune repertoire as a basic principle that governs the function of immunity. The CDR functions as a consequence of system's thermodynamically determined intrinsic tendency to acquire new states of inner equilibrium and equilibrium against the environment. Consequently, immune repertoire undergoes continuous dual (two-way) resetting: against the physiologic continuous changes of self and against the continuously changing environment. The CDR-based dynamic concept of immunity describes mechanisms of self-regulation, tolerance, and immunosenescence, and emphasizes the significance of immune system's compartmentalization in the pathogenesis of ICIC. The CDR concept's relative simplicity and concomitantly documented congruency with empirical, clinical, and experimental data suggest it may represent a plausible theoretical framework to better understand the human immune system function.
[Mh] Termos MeSH primário: Fenômenos do Sistema Imunológico
Sistema Imunitário/fisiologia
[Mh] Termos MeSH secundário: Animais
Asma/imunologia
Doenças Autoimunes/etiologia
Doenças Autoimunes/imunologia
Seres Humanos
Hipersensibilidade/imunologia
Tolerância Imunológica
Imunossenescência
Tolerância a Antígenos Próprios/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170322
[Lr] Data última revisão:
170322
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170302
[St] Status:MEDLINE
[do] DOI:10.1155/2017/3760238


  6 / 236 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Bauer, Moisés E
Texto completo
[PMID]:28191474
[Au] Autor:Pavón L; Besedosky H; Bottasso O; Velasco-Velázquez MA; Bauer ME
[Ad] Endereço:Department of Psychoimmunology, National Institute of Psychiatry "Ramón de la Fuente", Calzada México-Xochimilco 101, Colonia San Lorenzo Huipulco, Tlalpan, 14370 Mexico City, Mexico.
[Ti] Título:Clinical and Experimental Immunomodulation 2016.
[So] Source:J Immunol Res;2017:3152956, 2017.
[Is] ISSN:2314-7156
[Cp] País de publicação:Egypt
[La] Idioma:eng
[Mh] Termos MeSH primário: Imunomodulação
[Mh] Termos MeSH secundário: Animais
Seres Humanos
Fenômenos do Sistema Imunológico
[Pt] Tipo de publicação:EDITORIAL
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170323
[Lr] Data última revisão:
170323
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170214
[St] Status:MEDLINE
[do] DOI:10.1155/2017/3152956


  7 / 236 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28159733
[Au] Autor:Hou TZ; Verma N; Wanders J; Kennedy A; Soskic B; Janman D; Halliday N; Rowshanravan B; Worth A; Qasim W; Baxendale H; Stauss H; Seneviratne S; Neth O; Olbrich P; Hambleton S; Arkwright PD; Burns SO; Walker LS; Sansom DM
[Ad] Endereço:Institute of Immunity and Transplantation, Division of Infection & Immunity, School of Life and Medical Sciences, University College London, Royal Free Hospital, London, United Kingdom.
[Ti] Título:Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations.
[So] Source:Blood;129(11):1458-1468, 2017 Mar 16.
[Is] ISSN:1528-0020
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Heterozygous CTLA-4 deficiency has been reported as a monogenic cause of common variable immune deficiency with features of immune dysregulation. Direct mutation in CTLA-4 leads to defective regulatory T-cell (Treg) function associated with impaired ability to control levels of the CTLA-4 ligands, CD80 and CD86. However, additional mutations affecting the CTLA-4 pathway, such as those recently reported for LRBA, indirectly affect CTLA-4 expression, resulting in clinically similar disorders. Robust phenotyping approaches sensitive to defects in the CTLA-4 pathway are therefore required to inform understanding of such immune dysregulation syndromes. Here, we describe assays capable of distinguishing a variety of defects in the CTLA-4 pathway. Assessing total CTLA-4 expression levels was found to be optimal when restricting analysis to the CD45RA Foxp3 fraction. CTLA-4 induction following stimulation, and the use of lysosomal-blocking compounds, distinguished CTLA-4 from LRBA mutations. Short-term T-cell stimulation improved the capacity for discriminating the Foxp3 Treg compartment, clearly revealing Treg expansions in these disorders. Finally, we developed a functionally orientated assay to measure ligand uptake by CTLA-4, which is sensitive to ligand-binding or -trafficking mutations, that would otherwise be difficult to detect and that is appropriate for testing novel mutations in CTLA-4 pathway genes. These approaches are likely to be of value in interpreting the functional significance of mutations in the CTLA-4 pathway identified by gene-sequencing approaches.
[Mh] Termos MeSH primário: Proteínas Adaptadoras de Transdução de Sinal/genética
Antígeno CTLA-4/genética
Mutação
[Mh] Termos MeSH secundário: Antígeno CTLA-4/metabolismo
Linhagem Celular
Imunodeficiência de Variável Comum/genética
Fatores de Transcrição Forkhead/análise
Seres Humanos
Fenômenos do Sistema Imunológico/genética
Ligantes
Linfócitos T Reguladores/imunologia
Linfócitos T Reguladores/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adaptor Proteins, Signal Transducing); 0 (CTLA-4 Antigen); 0 (CTLA4 protein, human); 0 (FOXP3 protein, human); 0 (Forkhead Transcription Factors); 0 (Ligands); EC 2.7.10.- (LRBA protein, human)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170205
[St] Status:MEDLINE
[do] DOI:10.1182/blood-2016-10-745174


  8 / 236 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28104380
[Au] Autor:Bauduer F
[Ad] Endereço:UMR 5199 PACEA, université de Bordeaux, allée Geoffroy-Saint-Hilaire, 33615 Pessac cedex, France; Service d'hématologie, centre hospitalier de la Côte Basque, 64109 Bayonne cedex, France. Electronic address: frederic.bauduer@u-bordeaux.fr.
[Ti] Título:[Evolutionary medicine: A new look on health and disease].
[Ti] Título:La médecine évolutionniste : un nouveau regard sur la santé et les maladies..
[So] Source:Rev Med Interne;38(3):195-200, 2017 Mar.
[Is] ISSN:1768-3122
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:Evolutionary medicine represents an innovative approach deriving from evolutionary biology. It includes the initial Darwin's view, its actualization in the light of progresses in genetics and also dissident theories (i.e. non gene-based) particularly epigenetics. This approach enables us to reconsider the pathophysiology of numerous diseases, as for instance, infection, and our so-called diseases of civilization especially obesity, type 2 diabetes, allergy or cancer. Evolutionary medicine may also improve our knowledge regarding inter-individual variation in susceptibility to disease or drugs. Furthermore, it points out the impact of our behaviors and environment on the genesis of a series of diseases.
[Mh] Termos MeSH primário: Evolução Biológica
Doença/etiologia
Saúde
Medicina
[Mh] Termos MeSH secundário: Suscetibilidade a Doenças
Meio Ambiente
Epigênese Genética
Microbioma Gastrointestinal/fisiologia
Aptidão Genética
Seres Humanos
Fenômenos do Sistema Imunológico/fisiologia
Individualidade
Medicina/métodos
Medicina/tendências
Seleção Genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170928
[Lr] Data última revisão:
170928
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170121
[St] Status:MEDLINE


  9 / 236 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28042777
[Au] Autor:Mohamed H; Eltobgy M; Abdel-Rahman O
[Ad] Endereço:Faculty of Medicine, Ain Shams University, Cairo. Egypt.
[Ti] Título:Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials.
[So] Source:Anticancer Agents Med Chem;17(9):1228-1233, 2017.
[Is] ISSN:1875-5992
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Malignant pleural mesothelioma (MPM) is a hard to treat malignancy arising from the mesothelial surface of the pleura. Immune checkpoint inhibitors are considered a promising therapeutic strategy in many hardto- treat malignancies. In this review, we are trying to provide an in depth coverage of the prognostic value of immune checkpoints aberrations as well as discuss the different novel therapeutic strategies implementing these agents in the management of MPM.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Imunoterapia
Neoplasias Pulmonares/tratamento farmacológico
Mesotelioma/tratamento farmacológico
Neoplasias Pleurais/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Relação Dose-Resposta a Droga
Ensaios de Seleção de Medicamentos Antitumorais
Seres Humanos
Fenômenos do Sistema Imunológico/efeitos dos fármacos
Neoplasias Pulmonares/diagnóstico
Neoplasias Pulmonares/imunologia
Mesotelioma/diagnóstico
Mesotelioma/imunologia
Neoplasias Pleurais/diagnóstico
Neoplasias Pleurais/imunologia
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170103
[St] Status:MEDLINE
[do] DOI:10.2174/1871520617666170102151918


  10 / 236 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27983723
[Au] Autor:Quistad SD; Grasis JA; Barr JJ; Rohwer FL
[Ad] Endereço:Department of Biology, San Diego State University, San Diego, CA, USA.
[Ti] Título:Viruses and the origin of microbiome selection and immunity.
[So] Source:ISME J;11(4):835-840, 2017 Apr.
[Is] ISSN:1751-7370
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The last common metazoan ancestor (LCMA) emerged over half a billion years ago. These complex metazoans provided newly available niche space for viruses and microbes. Modern day contemporaries, such as cnidarians, suggest that the LCMA consisted of two cell layers: a basal endoderm and a mucus-secreting ectoderm, which formed a surface mucus layer (SML). Here we propose a model for the origin of metazoan immunity based on external and internal microbial selection mechanisms. In this model, the SML concentrated bacteria and their associated viruses (phage) through physical dynamics (that is, the slower flow fields near a diffusive boundary layer), which selected for mucin-binding capabilities. The concentration of phage within the SML provided the LCMA with an external microbial selective described by the bacteriophage adherence to mucus (BAM) model. In the BAM model, phage adhere to mucus protecting the metazoan host against invading, potentially pathogenic bacteria. The same fluid dynamics that concentrated phage and bacteria in the SML also concentrated eukaryotic viruses. As eukaryotic viruses competed for host intracellular niche space, those viruses that provided the LCMA with immune protection were maintained. If a resident virus became pathogenic or if a non-beneficial infection occurred, we propose that tumor necrosis factor (TNF)-mediated programmed cell death, as well as other apoptosis mechanisms, were utilized to remove virally infected cells. The ubiquity of the mucosal environment across metazoan phyla suggest that both BAM and TNF-induced apoptosis emerged during the Precambrian era and continue to drive the evolution of metazoan immunity.
[Mh] Termos MeSH primário: Evolução Biológica
Fenômenos do Sistema Imunológico/genética
Microbiota/fisiologia
Vírus/genética
[Mh] Termos MeSH secundário: Animais
Muco/imunologia
Muco/virologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161217
[St] Status:MEDLINE
[do] DOI:10.1038/ismej.2016.182



página 1 de 24 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde